Product Description
Tranexamic acid is used to treat heavy menstrual bleeding in women. This medicine may be used by teenage females, but is not intended for use before the start of menstruation. Tranexamic acid is an antifibrinolytic agent. It works by blocking the breakdown of blood clots, which prevents bleeding. (Sourced from: https://www.mayoclinic.org/drugs-supplements/tranexamic-acid-oral-route/description/drg-20073517)
Mechanisms of Action: Fibrinolysis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Topical,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Croatia, Germany, Hungary, Nigeria, Pakistan, Romania, Spain, Tanzania, United States, Zambia
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Anemia|Brain Hemorrhage, Traumatic|Hip Fracture|Injuries/wounds Unspecified|Sarcoma
Phase 2: Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2005-005103-41 | P2 |
Completed |
Unknown |
2025-01-30 |
|
| UTOTXA_2016 | P3 |
Active, not recruiting |
Sarcoma |
2019-01-31 |
|
| PRADO | P2 |
Active, not recruiting |
Unknown |
2022-05-07 |
|
| STOP-MSU | P2 |
Completed |
Stroke |
2023-05-28 |
|
| HYL-P004-003 | P3 |
Recruiting |
Injuries/wounds Unspecified |
2024-06-27 |
4% |
| WOMAN-2 | P3 |
Completed |
Anemia |
2023-09-20 |
|
| TIC-TOC | P3 |
Not yet recruiting |
Brain Hemorrhage, Traumatic |
2030-03-31 |
|
| NCT05047133 | P3 |
Recruiting |
Hip Fracture |
2022-07-01 |
|
| HYL-P004-003 | P3 |
Recruiting |
Injuries/wounds Unspecified |
2024-12-27 |
4% |
| TATRA | P3 |
Not yet recruiting |
Anemia |
2025-11-30 |